Description: BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Home Page: www.biocardia.com
BCDA Technical Analysis
320 Soquel Way
Sunnyvale,
CA
94085
United States
Phone:
650 226 0120
Officers
| Name | Title |
|---|---|
| Dr. Peter A. Altman Ph.D. | CEO, Pres & Director |
| Mr. David McClung | Chief Financial Officer |
| Mr. Edward M. Gillis | Sr. VP of Devices |
| Dr. Ian McNiece Ph.D. | Chief Scientific Officer |
| Dr. Sujith Shetty | Chief Medical Officer and VP of Clinical & Regulatory |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.5775 |
| Price-to-Sales TTM: | 23.7668 |
| IPO Date: | 2008-03-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |